BioCurex Inc. (OTCBB:BOCX) today announced results of its studies of RECAF blood test for cancer. BioCurex published that its RECAF can prevent 70% of unnecessary prostate biopsies. Results of study to be presented at the ISOBM ( International Society of Oncology and Biomarkers ) annual meeting in October, 2011. BioCurex highlighted that potential commercial impact […]